Humacyte is also developing its engineered vessel approach for use in building fistula access grafts for patients who need dialysis, as well as for people facing peripheral or coronary artery disease.

Additionally, the low median SYNTAX scores (12·0 in the overall population) and the fact that 22% of patients in the SAVR plus CABG group lacked left anterior descending artery involvement raise ...